Verdence Capital Advisors LLC Lowers Holdings in Quest Diagnostics Incorporated (NYSE:DGX)
Verdence Capital Advisors LLC Lowers Holdings in Quest Diagnostics Incorporated (NYSE:DGX)
Quest Diagnostics stock opened at $134.31 on Friday. The business has a 50-day simple moving average of $145.63 and a two-hundred day simple moving average of $140.90. The company has a market cap of $14.95 billion, a P/E ratio of 16.96 and a beta of 0.95. The company has a quick ratio of 1.10, a current ratio of 1.22 and a debt-to-equity ratio of 0.67. Quest Diagnostics Incorporated has a 52-week low of $120.40 and a 52-week high of $158.34. Verdence Capital Advisors LLC lessened its stake in Quest Diagnostics Incorporated (NYSE:DGX – Get Rating) by 10.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,432 shares of the medical research company's stock after selling 863 shares during the quarter. Verdence Capital Advisors LLC's holdings in Quest Diagnostics were worth $912,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
根據該公司在最近的 13F 與證券交易委員會（SEC）提交的文件中，根據該公司在第三季度（紐約證券交易所代碼：DGX-獲得評級）的 Verdence 資本顧問有限責任公司（紐約證券交易所：DGX-獲得評級）的股份減少了 10.4％。本季度出售 863 股後，該基金擁有該醫學研究公司股票的 7,432 股。Verdence 資本顧問有限責任公司在任務診斷的持有價值 $912,000 作為其最近的文件與證券交易委員會 (SEC).
Several other large investors have also recently modified their holdings of DGX. Price T Rowe Associates Inc. MD raised its position in shares of Quest Diagnostics by 548.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,125,530 shares of the medical research company's stock worth $149,673,000 after purchasing an additional 952,037 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Quest Diagnostics by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 14,014,030 shares of the medical research company's stock worth $1,917,961,000 after purchasing an additional 636,301 shares during the last quarter. Great West Life Assurance Co. Can purchased a new position in Quest Diagnostics in the 3rd quarter worth about $56,778,000. UBS Asset Management Americas Inc. raised its position in Quest Diagnostics by 42.2% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 1,153,772 shares of the medical research company's stock worth $153,429,000 after buying an additional 342,198 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in Quest Diagnostics by 7.0% in the 3rd quarter. Victory Capital Management Inc. now owns 3,223,518 shares of the medical research company's stock worth $395,494,000 after buying an additional 210,961 shares during the last quarter. Hedge funds and other institutional investors own 88.79% of the company's stock.
其他一些大型投資者最近還修改了他們對 DGX 的持有量。價格 T 羅威聯營公司 MD 在第二季度上調了其在任務診斷的股份位置 548.7％。T 羅威聯營股份有限公司現在擁有該醫學研究公司股票的 1,125,530 股價值 149,673,000 美元，在上一季度購買了額外的 952,037 股票後，該公司的股票價值為 149,673,000 美元。先鋒集團公司在第一季度提高了其在奎斯特診斷的股份地位 4.8％。領航集團股份有限公司在上一季度額外購買 636,301 股股份後，擁有該醫學研究公司股票的 14,014,030 股價值 1,917,961,000 美元。大西部人壽保險公司可以在價值約 56,778,000 美元的第三季度購買任務診斷的新位置。瑞銀資產管理美洲公司在第二季度將其在 Quest 診斷方面的地位提高了 42.2％。瑞銀資產管理美洲公司在上一季度額外購買了 342,198 股股票後，現在擁有該醫學研究公司股票的 1,153,772 股股票，價值 153,429,000 美元。最後，勝利資本管理公司在第三季度提高了 7.0％ 在任務診斷中的地位。勝利資本管理公司在上一季度額外購買 210,961 股股票後，現在擁有該醫學研究公司的 3,223,518 股股票，價值 395,494,000 美元。對沖基金和其他機構投資者擁有公司股票的 88.79%。
Insider Activity at Quest Diagnostics
探索診斷的內幕活動
In related news, SVP Michael E. Prevoznik sold 1,415 shares of the business's stock in a transaction that occurred on Friday, February 24th. The stock was sold at an average price of $141.42, for a total transaction of $200,109.30. Following the completion of the transaction, the senior vice president now directly owns 39,440 shares in the company, valued at approximately $5,577,604.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 1.70% of the stock is currently owned by corporate insiders.
在相關新聞中，高級副總裁邁克爾 ·E· 普雷沃茲尼克出售了 1,415 股業務的股票在發生在 2 月 24 日（星期五）的交易。該股票以 141.42 美元的平均價格出售，總交易量為 200,109.30 美元。交易完成後，高級副總裁現在直接擁有該公司 39,440 股股份，價值約為 5,577,604.80 美元。銷售在與 SEC 提交的文件中披露，該文件可在 此超連結。1.70％ 的股票目前由企業內部人士擁有。
Quest Diagnostics Trading Down 0.4 %
任務診斷交易下降 0.4%
Quest Diagnostics stock opened at $134.31 on Friday. The business has a 50-day simple moving average of $145.63 and a two-hundred day simple moving average of $140.90. The company has a market cap of $14.95 billion, a P/E ratio of 16.96 and a beta of 0.95. The company has a quick ratio of 1.10, a current ratio of 1.22 and a debt-to-equity ratio of 0.67. Quest Diagnostics Incorporated has a 52-week low of $120.40 and a 52-week high of $158.34.
任務診斷股票開盤 $134.31 上週五.該業務擁有 50 天的簡單移動平均線 145.63 美元，以及兩百天的簡單移動平均線 140.90 美元。該公司的市值為 1495 億美元，市盈率為 16.96 和 0.95 的測試版。該公司的快速比率為 1.10，流動比率為 1.22，債務與權益比率為 0.67。公司的任務診斷有 52 週低點為 120.40 美元和 52 周高點 158.34 美元。
Quest Diagnostics (NYSE:DGX – Get Rating) last announced its quarterly earnings data on Thursday, February 2nd. The medical research company reported $1.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.90 by $0.08. The company had revenue of $2.33 billion during the quarter, compared to the consensus estimate of $2.26 billion. Quest Diagnostics had a return on equity of 18.84% and a net margin of 9.57%. The firm's revenue was down 15.0% on a year-over-year basis. During the same period in the previous year, the company posted $3.33 EPS. Analysts predict that Quest Diagnostics Incorporated will post 8.72 EPS for the current year.
奎斯特診斷（紐約證交所代碼：DGX — 獲得評分）上次公佈了其季度收益數據，週四，2 月 2 日。這家醫學研究公司報告了本季度每股盈利 1.98 美元，超過了分析師的 1.90 美元的共識估計，達到 0.08 美元。該公司在本季度的收入為 22.3 億美元，而共識估計為 226 億美元。奎斯特診斷的股權回報率為 18.84％，淨利潤率為 9.57％。公司的收入較去年同期下降 15.0%。在上一年同期，該公司每股收益 3.33 美元。分析師預測，奎斯特診斷公司將在本年度發布 8.72 每股盈利。
Quest Diagnostics declared that its board has authorized a stock buyback program on Thursday, February 2nd that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 6% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's board of directors believes its stock is undervalued.
奎斯特診斷宣布，其董事會已於 2 月 2 日（星期四）授權了一項股票回購計劃，該計劃允許該公司回購 10 億美元的股票。這種回購授權允許醫學研究公司通過公開市場購買回高達 6％ 的股票。股票回購計劃通常表明公司董事會認為其股票價值被低估。
Quest Diagnostics Increases Dividend
任務診斷增加紅利
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 24th. Investors of record on Monday, April 10th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Thursday, April 6th. This is an increase from Quest Diagnostics's previous quarterly dividend of $0.66. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.11%. Quest Diagnostics's payout ratio is 33.33%.
該業務最近還披露了季度股息，該股息將於 4 月 24 日（星期一）支付。4 月 10 日（星期一）創紀錄的投資者將派發每股 0.71 美元的股息。該股息的除息日期為 4 月 6 日（星期四）。這是奎斯特診斷公司之前季度股利 0.66 美元的增加。這代表每年 2.84 美元的股息，股息收益率為 2.11%。任務診斷的支付比率為 33.33％。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of equities analysts have weighed in on the company. Morgan Stanley boosted their target price on Quest Diagnostics from $146.00 to $158.00 and gave the stock an "equal weight" rating in a research report on Friday, January 6th. StockNews.com lowered Quest Diagnostics from a "buy" rating to a "hold" rating in a research report on Friday, February 3rd. Credit Suisse Group boosted their target price on Quest Diagnostics from $143.00 to $146.00 and gave the stock a "neutral" rating in a research report on Wednesday, January 25th. Mizuho boosted their target price on Quest Diagnostics from $160.00 to $165.00 and gave the stock a "buy" rating in a research report on Wednesday, December 14th. Finally, Wells Fargo & Company boosted their price target on Quest Diagnostics from $135.00 to $140.00 and gave the company an "equal weight" rating in a research note on Friday, February 3rd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Quest Diagnostics currently has a consensus rating of "Hold" and an average target price of $150.00.
一些股票分析師對該公司進行了權衡。摩根士丹利將 Quest 診斷的目標價格從 146.00 美元提高到 158.00 美元，並在 1 月 6 日（星期五）的一份研究報告中給予該股票「同等權重」評級。Stocknews.com 在 2 月 3 日（星期五）的研究報告中將任務診斷從「購買」評級降低為「持有」評級。瑞士信貸集團將 Quest 診斷的目標價格從 143.00 美元提高到 146.00 美元，並在 1 月 25 日（週三）的一份研究報告中給予該股「中性」評級。瑞穗將其奎斯特診斷的目標價格從 160.00 美元提高到 165.00 美元，並在 12 月 14 日（週三）的一份研究報告中給予該股票「買入」評級。最後，富國銀行公司將 Quest 診斷的價格目標從 135.00 美元提高到 140.00 美元，並在 2 月 3 日（星期五）的一份研究報告中給予該公司「同等權重」評級。一位股票研究分析師對該股票進行了賣出評級，其中六名股票給予持有評級，其中三名股票向該公司發出了買入評級。根據 MarketBeat.com 的數據，奎斯特診斷目前的共識評級為「持有」，平均目標價為 150.00 美元。
About Quest Diagnostics
關於任務診斷
(Get Rating)
(取得評分)
Quest Diagnostics, Inc engages in the provision of diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers.
奎斯特診斷公司從事診斷測試，信息和服務的提供。它通過診斷信息服務（DIS）和所有其他部分運行。DIS 部門為患者，臨床醫生，醫院，健康計劃和雇主提供診斷信息服務。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Quest Diagnostics (DGX)
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- 獲取有關任務診斷（DGX）的研究報告的免費副本
- 市場節拍週的回顧 — 3/6 — 3/10
- 2 海上鑽探股票將提取巨額利潤
- 前面有兩位數字的三個主要股票
- 投資者可以信任消費者提升美國戶外品牌嗎？
- 如何購買高收益股息股票
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收 Quest 診斷的最新消息與評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Quest 診斷和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
